# HEZQARA Phases 9–13

This document records the production implementation boundary for the final roadmap block.

## Phase 9 — AI Reliability, Evaluation & Governance

- AI capability catalog and risk tiers.
- Versioned capability metadata and evaluation suites.
- Human approval and emergency controls.
- Execution telemetry, failure taxonomy, policy decisions, and audit evidence.
- Tenant isolation at RLS and relational-integrity layers.
- Synthetic evaluation only; no production accuracy or clinical-performance claim.

## Phase 10 — Production & Enterprise Hardening

- Database/readiness health checks.
- Tenant security posture visibility.
- Production configuration remains environment-driven.
- Security-event and health-check persistence is tenant scoped.
- No secrets are stored in source control.

## Phase 11 — Scale, Multi-Clinic & Platform Infrastructure

- Tenant plan limits for executions, communications, users, and locations.
- Daily usage accounting with idempotent upserts.
- Durable tenant-scoped platform job records with idempotency keys.
- Usage and limits are exposed through authenticated platform APIs.

## Phase 12 — Commercial / Enterprise Productization

- Starter, Growth, Professional, and Enterprise plan catalog.
- Tenant subscription state.
- Plan-to-entitlement mapping.
- Subscription change events.
- Provider identifiers are stored as references only; payment-provider behavior remains configuration dependent.

## Phase 13 — Launch, Growth & Market Expansion

- Structured onboarding checklist.
- Lead capture model and source/campaign attribution.
- Referral model.
- Growth campaign event model.
- Authenticated platform onboarding APIs.

## Verification contract

The implementation branch is validated independently from the normal development workflow. The final validation workflow applies migrations 001–029, executes backend/security tests, proves tenant isolation for the new platform surfaces, and performs a production-like backend import plus frontend lint/type-check/build.

A green workflow is required before Phases 9–13 are declared closed. This document does not constitute evidence of production deployment, customer traction, compliance certification, or clinical efficacy.
